MedChunk
Medically reviewed

Amyloidosis and Ankylosing Spondylitis: How They Are Linked

Learn how ankylosing spondylitis may be linked to AA amyloidosis, why chronic inflammation matters, how the kidneys can be affected, and how doctors diagnose and manage this rare complication.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 19, 2026 13 min read

Amyloidosis and ankylosing spondylitis are linked because long-lasting inflammation from ankylosing spondylitis may contribute to a rare condition called AA amyloidosis. In this condition, abnormal protein deposits build up in organs, particularly the kidneys, and can interfere with their normal function. Although this complication is uncommon, understanding the connection can help people with ankylosing spondylitis recognize why controlling inflammation and monitoring kidney health matter.

What Is the Connection Between Amyloidosis and Ankylosing Spondylitis?

Ankylosing spondylitis (AS) is a long-term inflammatory condition that mainly affects the spine and the joints connecting the spine to the pelvis. In some people, inflammation can also affect other parts of the body. Amyloidosis is a group of conditions in which abnormal proteins called amyloid accumulate in tissues and organs. These deposits can gradually interfere with how affected organs work. The type most relevant to ankylosing spondylitis is **AA amyloidosis**, also known as secondary amyloidosis or inflammatory amyloidosis. According to the Australian Amyloidosis Network, AA amyloidosis can develop in people with long-standing inflammatory conditions, including ankylosing spondylitis. The connection involves persistent inflammation rather than a direct effect of the spinal changes associated with AS. Importantly, having ankylosing spondylitis does not mean someone will develop amyloidosis. Most people with AS do not develop this complication.

How Can Ankylosing Spondylitis Lead to AA Amyloidosis?

The connection involves a blood protein called serum amyloid A (SAA). Serum amyloid A is an inflammation-related protein. The liver produces more of it when the body responds to inflammation or infection. In people with ongoing inflammatory diseases, SAA levels may remain elevated for extended periods. When these levels stay unusually high, some of the protein can form abnormal deposits called AA amyloid. These deposits can collect in different organs and gradually affect their function. The process can be understood in three stages:

1. Long-term inflammation develops

Ankylosing spondylitis causes persistent inflammation that may continue for many years. In some people, inflammation remains active despite periods when symptoms improve.

2. Serum amyloid A levels increase

Ongoing inflammation can stimulate the liver to produce more SAA protein. If inflammation remains active, elevated SAA levels may persist.

3. Amyloid deposits accumulate in organs

Over time, SAA protein can contribute to the formation of AA amyloid deposits. These deposits collect in tissues and may gradually interfere with normal organ function. The Australian Amyloidosis Network explains that prolonged elevation of SAA is associated with the development of AA amyloid deposits. However, researchers do not fully understand why some people with long-standing inflammatory diseases develop amyloidosis while others with similar conditions do not.

Does Ankylosing Spondylitis Increase the Risk of Amyloidosis?

Research suggests that people with ankylosing spondylitis have a higher relative risk of developing amyloidosis than people without the condition. A population-based longitudinal study published in the journal Rheumatology in 2021 examined 5,911 people with ankylosing spondylitis and compared them with 29,007 matched individuals without AS. The researchers found that:
  • The incidence of amyloidosis was higher among people with ankylosing spondylitis.
  • The adjusted risk of developing amyloidosis was more than six times higher in the AS group.
  • A greater burden of other health conditions was associated with increased susceptibility to amyloidosis among people with AS.
  • People with both AS and amyloidosis had a higher risk of developing end-stage kidney disease requiring dialysis.
These findings come from the study The Risk, Predictors and Outcomes of Amyloidosis in Ankylosing Spondylitis. The results demonstrate an association between AS and amyloidosis, but they do not establish that every person with AS is at substantial risk. The study also examined amyloidosis overall, so its findings should not be interpreted as a precise estimate of AA amyloidosis alone.

Why Are the Kidneys Particularly Important?

The kidneys are the organs most commonly affected by AA amyloidosis. They normally filter waste products and excess fluid from the blood while keeping important proteins inside the body. When amyloid deposits accumulate in kidney tissue, they can damage the filtering structures. As a result, proteins may leak into the urine, and the kidneys may gradually lose their ability to filter blood effectively. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), AA amyloidosis is associated with chronic inflammatory conditions and can cause kidney damage. Kidney involvement is particularly important because early changes may not cause obvious discomfort.

Possible signs of kidney involvement

Examples of symptoms and changes that may occur when amyloidosis affects the kidneys include:
  • Foamy or frothy urine: This may occur when excess protein passes into the urine.
  • Swelling in the legs or ankles: Fluid may accumulate when the kidneys are unable to maintain normal fluid and protein balance.
  • Swelling around the eyes: This can occur with significant protein loss through the kidneys.
  • Changes in kidney function: Blood tests may show that the kidneys are not filtering waste products as effectively as expected.
  • Fatigue: Kidney dysfunction and other effects of amyloidosis may contribute to persistent tiredness.
These changes can have several possible causes. They should be assessed in the context of a person's medical history and test results.

Can Amyloidosis Affect Organs Other Than the Kidneys?

Yes. Although kidney involvement is particularly common in AA amyloidosis, deposits can also affect other organs. The organs involved and the effects depend on where amyloid accumulates. Other possible sites include:

Digestive system

Amyloid deposits can affect the digestive tract. Some people may experience abdominal discomfort, nausea, changes in appetite, diarrhoea, or other digestive problems.

Liver and spleen

Amyloid accumulation may affect these organs and interfere with their normal function. Enlargement of the liver or spleen can occur in some cases.

Heart and nervous system

Heart and nerve involvement can occur in amyloidosis, although these organs are less commonly affected in AA amyloidosis than in certain other types. The Australian Amyloidosis Network identifies the kidneys, spleen, digestive tract, and liver as common sites of AA amyloid involvement. This distinction matters because not all types of amyloidosis affect the same organs in the same way.

Is AA Amyloidosis the Same as Other Types of Amyloidosis?

No. Amyloidosis is not a single disease with one cause. Different types develop from different proteins, and the treatment depends on identifying the specific type. The main types include:
Type Main association or cause
AA amyloidosis Long-term inflammation or chronic infection.
AL amyloidosis Abnormal immunoglobulin light-chain proteins produced by plasma cells.
ATTR amyloidosis Abnormal transthyretin protein, which may be inherited or develop with aging.
Dialysis-related amyloidosis Accumulation of beta-2 microglobulin in people receiving long-term dialysis.
According to MedlinePlus, amyloidosis involves abnormal protein deposits that can affect organs such as the kidneys and heart. Symptoms and treatment depend on the type. For someone with ankylosing spondylitis, AA amyloidosis is the form most directly associated with chronic inflammation. However, a history of AS does not automatically establish that any amyloid deposits are caused by the inflammatory disease. Doctors must identify the actual protein involved.

How Do Doctors Diagnose Amyloidosis in Someone With Ankylosing Spondylitis?

Diagnosing amyloidosis involves identifying amyloid deposits, determining their protein type, and assessing which organs are affected. Doctors may consider this possibility when someone with a long-standing inflammatory condition develops unexplained kidney problems, particularly protein in the urine. The evaluation may involve several steps.

1. Blood tests

Blood tests can help assess kidney function and identify changes associated with inflammation. Depending on the clinical situation, doctors may measure:
  • Creatinine and estimated glomerular filtration rate (eGFR) to assess kidney function.
  • Serum albumin to check blood protein levels.
  • C-reactive protein (CRP) to assess inflammation.
  • Serum amyloid A levels when available and clinically appropriate.
These tests provide useful information but cannot independently confirm AA amyloidosis.

2. Urine tests

Urine testing helps identify protein leakage, which can be an early sign of kidney damage. Doctors may request:
  • A urine protein test.
  • A urine albumin-to-creatinine ratio.
  • Additional urine testing to assess the amount of protein being lost.
These results help determine whether further kidney investigations are needed.

3. Tissue biopsy

A biopsy is an important part of confirming amyloidosis. During this procedure, a small tissue sample is collected and examined under a microscope. Depending on the clinical situation, a kidney biopsy or a sample from another suitable tissue may be considered. Special staining methods, including Congo red staining, can help identify amyloid deposits. Further laboratory testing is needed to determine the exact amyloid protein type. This distinction is essential because AA amyloidosis, AL amyloidosis, and other forms require different treatment approaches.

4. Additional tests to assess organ involvement

If amyloidosis is confirmed or strongly suspected, doctors may recommend additional investigations based on the organs involved. These may include:
  • Imaging tests to examine affected organs.
  • Heart investigations when cardiac involvement is suspected.
  • Further blood and urine tests to monitor kidney function.
  • Additional specialist investigations to identify the amyloid subtype.
The NIDDK's guidance on amyloidosis and kidney disease describes the use of medical history, physical examination, blood tests, urine tests, and kidney biopsy in evaluating kidney-related amyloidosis.

Can Treating Ankylosing Spondylitis Help Prevent AA Amyloidosis?

Controlling long-term inflammation is an important part of reducing the risk of AA amyloidosis. The goal is to reduce persistent inflammatory activity and prevent prolonged elevation of serum amyloid A protein. Treatment for ankylosing spondylitis is individualized and may include:
  • Nonsteroidal anti-inflammatory drugs (NSAIDs): These medicines can help manage pain and inflammation in appropriate patients.
  • Biologic medicines: Certain biologic treatments can reduce inflammatory activity in people who need additional disease control.
  • Other disease-modifying treatments: Treatment choices depend on the pattern of inflammation and the joints or other organs involved.
  • Regular rheumatology follow-up: Ongoing assessment helps doctors understand whether inflammation is adequately controlled.
Importantly, these treatments are used to manage ankylosing spondylitis. Their use should not be interpreted as a guarantee that amyloidosis will be prevented. The NIDDK explains that treating the underlying chronic inflammatory condition and keeping inflammation under control may help prevent AA amyloidosis.

What Happens If Someone Develops Both Conditions?

When AA amyloidosis develops alongside ankylosing spondylitis, treatment generally involves addressing both the underlying inflammatory disease and the affected organs. The medical team may include a rheumatologist, nephrologist (kidney specialist), and an amyloidosis specialist when available. Treatment has two main goals.

Control the underlying inflammation

Doctors work to reduce the inflammatory activity associated with ankylosing spondylitis. This may involve reviewing existing treatment, adjusting medicines, and monitoring inflammatory markers when appropriate. Reducing the production of serum amyloid A is an important objective in managing AA amyloidosis.

Protect the affected organs

If the kidneys are affected, treatment may focus on managing protein loss, fluid retention, blood pressure, and declining kidney function. When kidney damage becomes advanced, some people may need dialysis or may be considered for kidney transplantation. Treatment outcomes depend on how much organ damage has already occurred and whether the underlying inflammation can be controlled. According to the Australian Amyloidosis Network, reducing the underlying inflammatory activity and SAA levels may help stabilize amyloid deposits and, in some cases, allow improvement in organ function. However, established kidney damage does not always reverse, even when inflammation is brought under control.

When Should Someone With Ankylosing Spondylitis Seek Medical Evaluation?

People living with ankylosing spondylitis should discuss new or persistent symptoms with their healthcare team, particularly when they may indicate changes in kidney function. It is useful to seek medical assessment if there is:
  • New or persistent swelling in the ankles, legs, or around the eyes.
  • Repeatedly frothy or unusually foamy urine.
  • Unexplained changes in urine output.
  • Persistent fatigue that is not easily explained.
  • Unexplained weight loss or ongoing digestive problems.
These symptoms do not specifically identify amyloidosis, but they may justify further investigation. People with long-standing or poorly controlled inflammatory disease can discuss with their rheumatologist whether kidney function and urine protein testing are appropriate as part of their ongoing care. Sudden breathlessness, chest pain, or a marked reduction in urine output requires prompt medical assessment.

What Is the Outlook for People With Both Conditions?

The outlook depends on several factors, including the extent of amyloid deposition, the organs involved, kidney function, and how effectively the underlying inflammation can be controlled. Ankylosing spondylitis alone does not mean that amyloidosis will develop. For people who do develop AA amyloidosis, early recognition and appropriate management of the inflammatory disease are important. Some individuals may experience stabilization of amyloid-related organ damage when inflammation and SAA production are reduced. Others may have lasting kidney damage that requires ongoing specialist care. The important point is that amyloidosis is a recognized but uncommon complication of chronic inflammatory disease. Appropriate management of ankylosing spondylitis and attention to kidney health can help doctors identify and address potential problems.

Frequently Asked Questions

Common questions about the relationship between ankylosing spondylitis and amyloidosis.

Can ankylosing spondylitis cause amyloidosis?

Long-standing inflammation associated with ankylosing spondylitis may contribute to AA amyloidosis. This happens when prolonged inflammation increases serum amyloid A protein, which can form abnormal deposits in organs. However, amyloidosis is an uncommon complication, and most people with ankylosing spondylitis do not develop it.

What type of amyloidosis is associated with ankylosing spondylitis?

AA amyloidosis, also called secondary amyloidosis, is the type most closely associated with ankylosing spondylitis. It develops in connection with prolonged inflammation and most commonly affects the kidneys.

Does amyloidosis from ankylosing spondylitis always affect the kidneys?

No. Although the kidneys are the most commonly affected organs in AA amyloidosis, deposits can also involve the liver, spleen, and digestive tract. The pattern of organ involvement varies between individuals.

Can controlling ankylosing spondylitis reduce the risk of amyloidosis?

Controlling chronic inflammation may help reduce the risk of AA amyloidosis. Effective management can also lower serum amyloid A levels, which are involved in the formation of AA deposits. However, controlling ankylosing spondylitis does not guarantee that amyloidosis will never develop.

Can AA amyloidosis cause kidney failure in people with ankylosing spondylitis?

Yes. When AA amyloid deposits damage kidney tissue, kidney function can gradually decline. In advanced cases, kidney failure may develop, and some people may require dialysis or kidney transplantation. Early identification and management of the underlying inflammation are important.

Citations

  1. Australian Amyloidosis Network – AA Amyloidosis
  2. The Risk, Predictors and Outcomes of Amyloidosis in Ankylosing Spondylitis – Rheumatology, Oxford Academic
  3. National Institute of Diabetes and Digestive and Kidney Diseases – Amyloidosis and Kidney Disease
  4. MedlinePlus – Amyloidosis
  5. NHS – Amyloidosis
Share this article